Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.

Use of enoxaparin in end-stage renal disease / Lai, Silvia; Bettina, Coppola. - In: KIDNEY INTERNATIONAL. - ISSN 0085-2538. - 84:3(2013), pp. 433-436. [10.1038/ki.2013.163]

Use of enoxaparin in end-stage renal disease

LAI, SILVIA;
2013

Abstract

Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
2013
01 Pubblicazione su rivista::01a Articolo in rivista
Use of enoxaparin in end-stage renal disease / Lai, Silvia; Bettina, Coppola. - In: KIDNEY INTERNATIONAL. - ISSN 0085-2538. - 84:3(2013), pp. 433-436. [10.1038/ki.2013.163]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/535109
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact